Welcome to our dedicated page for Nkarta SEC filings (Ticker: NKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech like Nkarta, Inc. (NKTX) means wading through pages of complex immunotherapy jargon, trial data, and risk factors. If you have ever searched for “Nkarta SEC filings explained simply,” you already know how time-consuming that can be.
Our platform solves that problem. Stock Titan’s AI reviews every submission to EDGAR in real time, from the Nkarta quarterly earnings report 10-Q filing to sudden Nkarta 8-K material events explained. Plain-language summaries flag shifts in cash runway, R&D spend, and clinical milestones, delivering the Nkarta annual report 10-K simplified you wish the company itself provided. Need immediate insight into insider sentiment? Receive alerts for Nkarta Form 4 insider transactions real-time, including detailed tables of Nkarta executive stock transactions Form 4.
Investors typically ask where to locate “Nkarta proxy statement executive compensation” or how to interpret “Nkarta earnings report filing analysis.” Our interface groups disclosures by topic and answers those natural-language questions on the spot. You can:
- Drill into Nkarta insider trading Form 4 transactions to spot buying before data readouts
- Compare pipeline spend across quarters without combing through footnotes
- Export red-lined changes between filings for faster diligence
Whether you are understanding Nkarta SEC documents with AI for the first time or monitoring ongoing developments, our real-time engine keeps you ahead of each disclosure so you can act with confidence.
Nkarta reported a significant insider transaction involving Chief Medical Officer and Head of R&D, Shawn Marshall Rose. On June 23, 2025, Rose was granted stock options to purchase 500,000 shares of common stock at an exercise price of $1.75 per share.
The stock options have a structured vesting schedule:
- 25% of the options vest on July 23, 2026
- Remaining 75% vest in 36 equal monthly installments following June 23, 2026
- Options expire on June 22, 2035
This grant suggests a long-term retention strategy for a key executive, with the low exercise price potentially indicating recent stock price challenges or an incentive-focused compensation structure. The substantial size of the grant (500,000 shares) reflects the senior leadership position and importance of the R&D function to the company.
Form 3 Initial Statement of Beneficial Ownership filed for Nkarta (NKTX) on June 28, 2025, reporting the beneficial ownership status of Shawn Marshall Rose, who has been appointed as the company's Chief Medical Officer and Head of Research & Development.
Key details:
- Filing Date: June 28, 2025
- Event Date: June 23, 2025
- Location: South San Francisco, CA
- Filing Type: Individual filing
- Current Holdings: No securities beneficially owned
This Form 3 indicates that the executive currently holds no derivative or non-derivative securities in the company. The filing was signed by Bridgette Housley as Attorney-in-Fact on June 25, 2025, and includes a Power of Attorney as Exhibit 24.
Nkarta, Inc. (NKTX) – Form 4 Insider Transaction Overview
CEO and Director Paul J. Hastings disclosed the sale of 1,790 common shares on 06/18/2025 at a weighted-average price of $1.79. The transaction was automatically executed to satisfy tax-withholding obligations triggered by the vesting and settlement of Restricted Stock Units and therefore was not a discretionary sale. Following the sale, Hastings continues to beneficially own 320,069 shares, which includes 2,000 shares purchased under Nkarta’s 2020 Employee Stock Purchase Plan on 05/31/2025.
No derivative securities were acquired or disposed of, and no additional transactions were reported. Given the small size of the sale—roughly 0.56% of the executive’s total holdings—the filing appears routine and does not signal any change in corporate strategy, financial position, or insider sentiment.
FAQ
What is the current stock price of Nkarta (NKTX)?
What is the market cap of Nkarta (NKTX)?
What is Nkarta, Inc. core business?
How does Nkarta generate its cell therapy products?
What advantages do allogeneic cell therapies offer?
What are the key diseases Nkarta targets?
How does Nkarta ensure the safety of its cell therapies?
What differentiates Nkarta from other cell therapy companies?
Where is Nkarta, Inc. headquartered?
How does Nkarta address the challenges in cell therapy manufacturing?
What kind of clinical evidence supports Nkarta's approach?
